Publications
Probity Medical Research has compiled journals, articles and presentations for your personal review. Please use the search features below to find an article.
If you would like to request an article for personal review please complete the registration form. These publications are for personal use only and cannot be distributed.
Already granted access to an article?
If you cannot find the article you are looking for please contact Probity Medical Research.
Journals, Articles and Presentations
Articles by Publication Year
Efficacy and Safety Results From a Phase III, Randomized Controlled Trial Comparing Two Dosing Regimens of ABT-874 to Placebo in Patients With Moderate to Severe Psoriasis
Presented at the 2010 Winter Clinical Dermatology Conference in Kauai, Hawaii, January 23-27, 2010
Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet
Archives of Dermatology 2011 Apr;147(4):429-36. Epub 2010 Dec 20.
Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the Phoenix 1 trial
British Journal of Dermatology 2010 Jan;162(1):137-146. Epub 2009 Nov 9.
Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations
Journal of American Acadamy of Dermatology 2010 Oct;63(4):571-9.
A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis
Journal of American Acadamy of Dermatology 2010 Mar;62(3):427-36.
Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies
International Journal of Dermatology 2010 Jul;49(7):818-828.
Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL
Journal of the American Academy of Dermatology, 2012 Feb;66(2):241-51. Epub 2011 Jul 14.
A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis
International Journal of Dermatology 2010 Dec;49(12):1368-75.
Long-Term Safety of Adalimumab for Psoriasis: An Analysis of All Adalimumab Exposure in All Global Clinical Trials
Presented at the AAD 68th Annual Meeting, Miami Beach, Florida, March 5-9, 2010
Tasocitinib (CP-690,550), an Oral Janus Kinase Inhibitor, Significantly Improves the Symptoms of Moderate-to-Severe Psoriasis with Short-term Treatment
Presented at European Academy of Dermatology & Venereology (EADV), Gothenburg, Sweden, October 6-10, 2010
About PMR | Investigators | Experience | Locations | News | Publications | Privacy Policy | Contact | Sitemap |
Copyright 2014 Probity Medical Research Inc. All Rights Reserved.